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regulatory functions in the mammalian cell
division cycle
Shauna A Henley1,3,4 and Frederick A Dick1,2,3*

Abstract
The retinoblastoma (RB) family of proteins are found in organisms as distantly related as humans, plants, and
insects. These proteins play a key role in regulating advancement of the cell division cycle from the G1 to Sphases. This is achieved through negative regulation of two important positive regulators of cell cycle entry, E2F
transcription factors and cyclin dependent kinases. In growth arrested cells transcriptional activity by E2Fs is
repressed by RB proteins. Stimulation of cell cycle entry by growth factor signaling leads to activation of cyclin
dependent kinases. They in turn phosphorylate and inactivate the RB family proteins, leading to E2F activation and
additional cyclin dependent kinase activity. This propels the cell cycle irreversibly forward leading to DNA synthesis.
This review will focus on the basic biochemistry and cell biology governing the regulation and activity of
mammalian RB family proteins in cell cycle control.
Keywords: Cell cycle, Senescence, Transcription, Cyclin dependent kinase

Introduction
The retinoblastoma gene (RB1) was first identified based
on its mutation in a rare malignancy of the eye [1,2].
Shortly thereafter, viral oncogenes such as human papilloma virus E7, simian virus TAg, and adenovirus E1A,
were discovered to target it for inactivation during cellular transformation [3-5]. Based on sequence similarity,
and analogous interactions with viral proteins, two other
members of the RB family were identified, RBL1 and
RBL2 that code for the p107 and p130 proteins, respectively [6-11]. All three RB family members contain a
conserved domain referred to as the ‘pocket’ that interacts with the LXCXE motif found in viral proteins such
as TAg [12]. For this reason the RB family is also frequently called the pocket protein family. Pocket proteins
are present and thought to be central to the regulation
of proliferation in many diverse organisms [13]. Furthermore, deregulation of cell cycle control in cancer
requires the inactivation of their growth regulatory function [14].
* Correspondence: fdick@uwo.ca
1
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Canada
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In cancer, the RB1 gene is most frequently inactivated
through alterations to cyclin dependent kinase regulation,
however, in specific cancer types such as small cell lung
cancer and retinoblastoma it is uniformly abrogated by
direct mutation [15,16]. Reports of cancer derived mutations in the other RB family genes are less common,
nevertheless, experimental models of cancer using mice
that are deficient for these genes indicate that RBL1 and
RBL2 loss can enhance the cancer phenotype in RB1
mutant animals [17-20]. This suggests that the pocket
protein family has a collective role in cell cycle control
and tumor suppression. In most cancers, their ability to
regulate the cell cycle is likely bypassed by altering their
common upstream cyclin dependent kinase regulators
[15]. At the same time, differences in cancer derived
mutations between these genes suggest there may be
important biological differences within the RB family.
Research on the pocket proteins has often followed this
paradigm. In some circumstances the RB family of proteins are perceived to function analogously, while in
other instances they can have dramatically different functions. In this review the basic biochemical functions of
the pocket proteins will be emphasized. To guide readers
through the intricacies of this gene family, we will make
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Figure 1 Schematic representation of pRB, p107 and p130
open reading frames. (A) The central feature of RB-family proteins
is the pocket domain. It was originally defined as the minimal
domain necessary to bind to viral oncoproteins such as simian virus
TAg through their LXCXE motif, and is denoted as the ‘small pocket’
in this diagram. The ‘large pocket’ is the minimal growth
suppressing domain of RB-family proteins and it is capable of
binding E2F transcription factors as well as viral proteins. (B)
Comparison of open reading frame structures of each of the pocket
proteins. Note the additional features found in the p107 and p130
proteins, the kinase inhibitory site, the cyclin binding site, and the
insertion in the B-domain of the pocket. These provide the most
obvious differences between pRB and its relatives p107 and p130.

particular care to emphasize their similarities and contrast their differences.

The pocket protein family: pRB, p107, and p130
The RB family members share many structural properties (Figure 1A). The most extensive sequence homology
lies in the well-conserved, small pocket region, which
consists of A and B domains that are separated by a
flexible spacer region [21]. These A and B domains each
represent a single cyclin fold domain [22] and interact
such that the small pocket is self sufficient to form a
transcription repressor on its own [23-25]. The small
pocket is the minimal fragment of pRB that is capable
of interacting with viral oncoproteins, such as E1A and
TAg [26]. Even though they are derived from highly
unrelated viruses, these viral proteins each contain a
peptide motif called LXCXE that is essential for a stable
interaction with RB family proteins [4,27-30]. Crystallographic data has revealed that the LXCXE motif contacts a shallow groove on pRB, that is among the most
well conserved features among pocket protein family
members, and among pocket proteins across species
[22]. In addition to the viral proteins, a number of cellular proteins are reported to contain an LXCXE-like
motif that allows them to interact with pRB, p107 and
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p130 [12]. Many of these LXCXE containing proteins
possess chromatin regulating activity, or are components
of complexes that possess this activity. For these reasons, cellular proteins that contact this region of pocket
proteins are generally thought to negatively regulate
transcription and this will be described in more detail in
the ensuing sections of this review.
The combination of the small pocket and the C-terminal domain has been coined the large pocket (Figure
1A), and it is the minimal growth suppressing domain
found in RB family proteins [31]. The large pocket fragment is sufficient to interact with E2F family transcription factors and suppress their transcription [32,33].
Interaction with E2Fs is a common feature of RB family
proteins that plays a key role in their ability to control
proliferation. While E2F interactions are distinct from
LXCXE contacts, binding of viral oncoproteins through
the LXCXE motif tethers them in close proximity so
that a separate region on the viral protein can disrupt
binding between pocket proteins and E2Fs [34-36]. This
further emphasizes the importance of RB family-E2F
interactions because disrupting them is essential for
E1A viral oncogene driven transformation [37].
While the overall structure of the pocket domain is well
conserved between the three proteins, p107 and p130 are
more closely related to each other by sequence similarity
than either is to pRB [21]. Surprisingly, despite pRB’s
prominent description as the central tumor suppressor
within this family, and divergence in sequence similarity
[17], there are few obvious structural features that it possesses that are missing from p107 and p130 (Figure 1B).
Two unique features of pRB that have emerged recently
are a docking site used only by the E2F1 transcription
factor, and a short peptide region in the C-terminus that
is competitively occupied by cyclin/cyclin dependent
kinases (CDKs) or protein phosphatase 1 (PP1) (Figure
1B). The region of pRB that mediates these interactions
has little obvious sequence divergence from p107 and
p130 and the functional basis for these distinct aspects of
pRB function will be discussed extensively in later sections. So while there is little to distinguish pRB from its
siblings, somewhat surprisingly there are a number of
well known features in p107 and p130 that aren’t present
in pRB. Both p107 and p130 proteins contain insertions
in the B domain of their small pockets. In the case of
p130, this insert is subject to regulatory phosphorylation
to maintain protein stability [38]. Furthermore, p107 and
p130 contain longer spacer regions than pRB, and their
spacers allow them to interact stably with cyclin dependent kinase complexes [39-41]. Lastly, p107 and p130
contain an N-terminal region that serves to inhibit cyclin
dependent kinases [41].
The ability of pocket proteins to use these structural
features allows them to interact with a myriad of binding
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partners to control cell cycle advancement, and perhaps
much more. The uses of these interaction sites will be
expanded on and discussed in greater detail below.

The role of pocket proteins in an advancing cell
cycle
In order to illustrate the roles of pocket proteins in cell
cycle regulation we will begin by describing an idealized
mammalian cell cycle (Figure 2). In this way, our goal is
to summarize data from many experimental systems and
condense it into a model that best captures our current
understanding of RB family protein function throughout
the mammalian cell cycle.
Quiescence

Often referred to as G0, quiescence is a resting state
that is usually achieved through serum starvation of
cells in culture. Of the three pocket proteins, p130 has
the highest expression level in quiescent cells (Figure 3)
and at this stage of the cell cycle the majority of E2F
containing complexes contain p130 and E2F4 [42,43].
Recently it has been shown that p130 is part of a transcriptional repressor complex called DREAM, and it
functions to repress E2F target genes during G0 [44].
Under these growth conditions pRB expression is low,
but detectable in complex with E2Fs, while p107 is
nearly undetectable [42,43]. In addition to E2F targets,

Figure 3 Expression levels of pocket proteins throughout the
cell cycle. In G0, the most abundant pocket protein is p130. After
cells are stimulated to enter the cell cycle expression of pRB and
p107 are induced because they are E2F target genes themselves. At
the same time these pocket proteins increase, the expression level
of p130 begins to decline. In subsequent cell cycles pRB and p107
remain expressed at relatively constant levels, conversely, p130 is
relatively inabundant under these growth conditions. These unique
expression patterns offer clear, distinguishing characteristics of each
pocket protein family member.

pocket proteins also influence the expression of ribosomal and tRNA transcription in quiescence [45]. Both
pRB and p130 are capable of repressing the transcription of rRNA genes by RNA polymerase I; a function
that is not shared with p107 [46-48]. In addition, during

Figure 2 Model of cell cycle entry control by pocket protein. Beginning in the top left corner, quiescent cells repress transcription of E2F
targets genes largely through the actions of p130. As cells progress into G1, complexes containing p107 and a repressor E2F such as E2F4 begin
to replace p130. Furthermore, complexes of pRB and activator E2Fs such as E2F3 also become more abundant. Chromatin remodeling factors
(CRF) are recruited to these complexes and mediate alterations to the chromatin environment, preventing transcription of E2F responsive genes.
As a result, transcription of E2F target genes remains low until entry into S-phase. At the transition to S-phase, cyclin/CDK complexes
phosphorylate the pocket proteins, dissociating them from the E2F/DP duplexes and transcription of E2F target genes proceeds through S
phase. As part of this transition, the repressive heterochromatin changes that were present in G1 are reversed by the recruitment of new
enzymes by the E2Fs, histone acetyltransferases (HAT) are examples of this type of enzyme. Another important change at the start of S-phase is
the export of p130 and 107 proteins from the nucleus. At this point pocket proteins are thought to be relatively functionless until they are
dephosphorylated and reactivated at the end of mitosis so that they can regulate transcription again during the next G1 phase.
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G0 hypophosphorylated pRB binds to and represses
TFIIIB, suppressing transcription by RNA polymerase
III and reducing tRNA levels [49,50]. In contrast to
rRNA transcription, regulation of tRNA expression has
not been established for p107 or p130, it appears to be
pRB specific. G0 has characteristically low levels of both
rRNA and tRNA, which could be explained by pocket
protein repression of RNA polymerase I and/or III [45].
The increase in rRNA and tRNA levels as the cell enters
into the G1 phase has been proposed to involve phosphorylation of the pocket proteins to relieve this transcriptional repression [45]. While pRB has been found
to be phosphorylated at G0 exit [51], a direct link
between this phosphorylation and derepression of rRNA
and tRNA genes remains to be shown.
Progression of the cell cycle through G1 - regulation of
E2Fs

It is not completely clear what differences in proliferative control separate G0 from G1, however, as discussed
above, there are many differences in nucleic acid metabolism. The most distinguishing cell cycle marker of G0
compared to G1 is actually high level expression of
p130 [52]. Nevertheless, cells are capable of halting proliferation in G1 in subsequent cell cycles when p130
levels are low, indicating that arrest can take place at
this stage as well. In the context of an advancing cell
cycle that has started in G0, G1 is best thought of as a
transition to S-phase. The mechanisms that can induce
an arrest at this point in response to signals like DNA
damage or terminal differentiation require pocket protein function, but will be discussed later in the sections
on cell cycle exit.
In G1, all three pocket proteins share the ability to
interact with the E2F family of transcription factors.
There are eight E2F family members and among these,
E2Fs 1-5 are capable of binding to pocket proteins [53].
Each of these E2F proteins needs to heterodimerize with
one of three DP family partners that are capable of
binding to DNA [54]. The importance of the balance
between E2Fs and pocket protein expression levels in
cell cycle control is highlighted by experiments that
demonstrate that over expression of E2Fs can overcome
pocket protein dependent growth inhibition [55,56].
Conversely, knock out of E2F transcription factors can
suppress ectopic proliferation in Rb1 deficient mouse
embryos [57-59].
E2F family members 1-3 are referred to as the activator E2Fs because they induce transcription more
potently from E2F responsive promoters than other E2F
family proteins. E2Fs 4 and 5 are termed the repressor
E2Fs because they have limited activation potential. The
activator E2Fs associate exclusively with pRB [60]
whereas p107 and p130 preferentially bind to the
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repressor E2Fs, E2F4 and E2F5 [42,61-63]. In addition,
E2F4 is also detectable in complexes with pRB [42].
Because E2F4 and 5 lack a functional nuclear localization signal they rely on p107 and p130 to recruit them
to the nucleus [64,65]. This further ensures a transcriptional repressor role for these complexes because
neither p107, p130, E2F4 or E2F5 can efficiently localize
to E2F responsive promoters alone.
The composition of E2Fs and RB-family proteins at
cell cycle target genes in G1 is largely dictated by the
expression patterns of the pocket proteins (Figures 2
and 3). In early G1, p130-E2F4 is most abundant on the
promoters of E2F responsive genes, mediating transcriptional silencing of these genes [66,67]. In mid- to late
G1, when p130 levels drop and p107 levels increase,
p107 replaces it at E2F responsive promoters [67]. By
late G1, pRB-E2F complexes, whose levels have been
increasing throughout cell cycle entry also become more
abundant [66]. At this point pRB is associated with activator E2Fs in a configuration that masks the E2F activation domain and prevents activation of transcription
[32,68-70]. It is likely that pRB-E2F complexes are present at the promoters of E2F regulated genes, however,
chromatin immunoprecipitations by different research
groups have yielded varying results and this has left this
as an open question [66,67]. Regardless of the exact
mechanism by which each RB family protein works, it is
clear that in G0 and G1, the pocket proteins cooperate
to prevent the transcription of E2F regulated genes.
The E2F target genes that are subject to this regulation include cell cycle regulators such as cyclins A and
E, the activator E2Fs, and pRB and p107 themselves
[43,66,67,71]. Others include components of replication machinery such as the proliferating cell nuclear
antigen and DNA polymerase a, as well as enzymes
involved in nucleotide biosynthesis such as dihydrofolate reductase and thymidylate synthase [72,73]. How
individual pocket protein/E2F complexes select target
promoters beyond the E2F recognition sequence is not
known. Some genes, such as b-Myb, are specifically
regulated by p107 and p130 [43], while others, like
p107 itself, are exclusively regulated by pRB [43,67,74].
Others still are reported to be occupied unselectively
by all RB family members [66]. The concept of pocket
proteins controlling cell cycle advancement through
their interaction with E2Fs to negatively regulate transcription, at this stage of the cell cycle, is central to
current thinking on RB family function. This is further
underscored by the fact that viral oncogenes, such as
E1A, are capable of inducing expression of E2F responsive genes by disrupting pocket protein/E2F interactions and this disrupting activity is, as discussed
previously, required for viral oncogene induced cellular
transformation [37].
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A frequent companion to E2F regulation is the
recruitment of transcriptional repressors (often that possess chromatin regulating enzymatic activity) to pocket
protein-E2F complexes [53]. This allows specific enzymatic activities to be directed to very localized chromatin domains at these promoters. In the context of a cell
cycle that begins in quiescence and continues uninterrupted to the initiation of DNA synthesis, it is not clear
how important repressive modes of chromatin really are
for cell cycle progression through G1. For example, cells
from mice bearing a mutation in their pRB LXCXE
binding site, that disrupts the interaction between chromatin regulators and pRB, have no defect in regulating
progression through the G1 phase of the cell cycle [75].
However, deficiency for this interaction does compromise cell cycle exit [76]. As a result, regulation of chromatin by RB family proteins will be discussed later in
the context of cell cycle exit.
Progression of the cell cycle through G1 - regulation of
cyclin dependent kinases

The ability of pocket proteins to interact with E2Fs is
dependent on them being maintained in an under phosphorylated state [77]. The phosphorylation status of
pocket proteins is often determined by their migration in
SDS-PAGE, the slowest migrating forms are extensively
modified and don’t interact with E2Fs and this is
described as ‘hyperphosphorylated’. Alternatively, the
fastest migrating forms are modified at very few positions
and readily bind to E2F transcription factors, a state
often referred to as ‘hypophosphorylated’. It is imperative
for cells to maintain cyclin dependent kinase activity at
low levels until the end of G1. For this reason, discussion
of the mechanisms that control cyclin dependent kinase
activity are necessary for understanding pocket protein
function during the G1 phase (Figure 4).
Cyclin dependent kinases are controlled at many levels
from the assembly into complexes with cyclin subunits
to regulatory phosphorylation that controls catalytic
activity. However, the type of control that is most relevant to the activity of pocket proteins is at the level of
cyclin dependent kinase inhibitor (CKI) proteins because
they act immediately upstream of cyclin dependent
kinases to block catalytic activity (Figure 4). There are
two main classes of CKIs–the CIP/KIP family, which
consists of p21CIP1, p27KIP1 and p57KIP2 and the INK4
family, which consists of p16INK4A, p15INK4B, p18INK4C,
and p19 INK4D [78]. CIP/KIP family members contact
both the cyclin and CDK subunits when they bind and
inhibit kinase activity. They are not selective of cyclin
dependent kinases and are able to inhibit any cyclin
associated kinases that are found in G1. Alternatively,
the INK4A members can bind only cdk4 and cdk6 with
D-type cyclins [79].

Figure 4 The interrelationship of cell cycle regulatory
molecules in G1. Growth inhibitory and promoting signals impinge
on the regulation of cyclin dependent kinase inhibitors (CKI).
Growth promoting signals also directly lead to activation of cyclin
dependent kinases (CDK) in G1. The cyclin dependent kinases serve
to inactivate pocket proteins through phosphorylation leading to
E2F transcriptional increases and cell cycle advancement. Cell cycle
exit can be caused by activation of pocket proteins by
phosphatases. In addition to blocking E2F transcription, recently
activated pocket proteins also serve to negatively influence cyclin
dependent kinase activity and positively influence CKI abundance. In
this way, the regulatory molecules that control progression through
G1 are extensively regulated by one another.

As cells progress through the G1 phase, p27KIP1 plays
a key role in determining the onset of S-phase. In G1
p27 KIP1 expression levels are relatively high and the
kinase activity of cyclin E/cdk2 is low and this prevents
DNA synthesis from being triggered [79]. The first
kinase complexes to become active in G1 are cyclin D/
cdk4 or 6 and they begin to phosphorylate RB family
proteins [77]. As cells approach the end of G1, partial
phosphorylation of the pocket proteins allows some
transcription by activator E2Fs that begins to stimulate
production of cyclin E, and in turn creates more cyclin
E/cdk2 kinase activity [77,79]. The most significant
impediment to full activation of this kinase complex is
the interaction with and inhibition by p27KIP1 [79]. This
is ultimately overcome by cyclin E/cdk2 phosphorylating
p27 KIP1 resulting in it being targeted for degradation
and allowing for full activation of the kinase and ultimately entry into S-phase. Because of p27KIP1’s pivotal

Henley and Dick Cell Division 2012, 7:10
http://www.celldiv.com/content/7/1/10

role in regulating kinase activity to keep pocket proteins
active in G1, it is subjected to extensive regulation itself.
As an example of p27KIP1’s regulation, the growth promoting proto-oncogene c-myc has the ability to regulate
cyclin/CDK activity through p27 KIP1 . Cells lacking cmyc have a decreased growth rate due to increased
p27KIP1 and an associated decrease in cyclin/CDK activity [80], whereas expression of c-myc results in repression of p27KIP1 transcription [81].
In addition to the CIP/KIP and INK4 inhibitors, the
RB family members p107 and p130 also behave as cyclin
dependent kinase inhibitors by directly binding to
cyclin/CDK complexes [40,82-85]. The interaction
between p107 and p130 and cyclin/cdks allows them to
inhibit kinases to suppress growth [21,39,41], a function
that is not shared by pRB [86]. In fact, p107 is as potent
an inhibitor as p21 CIP1 [86]. For example, p107 and
p130 can use their cyclin dependent kinase inhibitory
activity to regulate the progression through G1 as
induction of p130 inhibits cyclin E/cdk2 and induces
p27KIP1 levels [87]. Two independent regions have been
shown to mediate p107 and p130’s ability to inhibit
cyclin A/cdk2 and cyclin E/cdk2 (Figure 1B). The first is
the spacer region between the A and B pockets, and the
second is a highly conserved region in the N-terminus
of p107 and p130 [39,41]. It is the combination of these
dual domains that allows p107 and p130 to inhibit
kinase activity. While the N-terminal region in p107 can
inhibit cyclin/CDK complexes, it has a weak affinity for
cyclin/CDK binding [86]. In contrast, the binding site in
the spacer region readily interacts with these kinases,
but cannot inhibit cyclin/CDK activity [86]. Mutagenesis
experiments using p130 showed that deletion of the
spacer region prevents binding of cyclin E and cyclin A
but that this mutant can still suppress cell growth, indicating that binding and inhibition of cyclin/CDKs are
mediated by different regions of the protein [39]. While
both p107 and p130 can act as cyclin dependent kinase
inhibitors when overexpressed, the circumstances where
this aspect of p107 and p130 function is most critical in
vivo has remained elusive.
It is known that pRB does not possess a kinase inhibitory domain that is analogous to the other family members (Figure 1B); however, it has the means to control
cyclin/CDK activity through inhibitor proteins. Specifically, it can interfere with the targeted degradation of
p27KIP1 to maintain G1 kinase activity at low levels at a
number of places in the degradation pathway [88,89].
Maintenance of p27 expression can be accomplished
when pRB acts as a scaffold that interacts with APCCdh1
and Skp2, simultaneously targeting Skp2 for ubiquitinmediated degradation [89]. Because Skp2 is an adaptor
that is necessary for targeting p27KIP1 for degradation,
this increases p27KIP1 levels and results in a net decrease
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of G1 CDK activity. Furthermore, pRB’s ability to interact with Skp2 also allows it to compete for binding with
phosphorylated p27 KIP1 [88]. Therefore, pRB also
directly blocks ubiquitination of p27KIP1 to maintain
inhibition of CDK activity. Studies have also shown that
p107 can decrease Skp2 levels and increase p27 KIP1 ,
delaying S-phase entry [90,91]. This suggests that p107
may also possess the ability to regulate p27KIP1 degradation. It should be emphasized that comparatively little is
known about how pocket proteins regulate p27 KIP1
expression in comparison with E2F regulation. It
remains unclear as to how important this control
mechanism is, even though some experiments have suggested that it may be as critical for controlling progression through G1 as E2F regulation [88,89].
The G1 to S-phase transition

Entry into S-phase is an important commitment for
mammalian cells. Once DNA replication has begun the
cell cycle must progress until cell division is complete.
The consequence of the cell cycle slipping backwards
into G1 after initiating replication is genome instability
and possibly cancer. As such, the commitment step to
initiate DNA replication possesses many features that
ensure cells progress exclusively from G1 to S-phase
and not in the reverse direction. Pocket proteins play a
key role in this mechanism.
Critical events that ensure G1 to S progression is unidirectional include feed forward loops that increase
cyclin dependent kinase activity, pocket protein phosphorylation, as well as the proteolytic degradation of
cyclin dependent kinase inhibitors such as p27KIP1 [79].
As intimated in the previous section on progression
through G1, cyclin dependent kinase activity rises
towards the end of G1 as does E2F transcriptional activity [92]. Since cyclin E/cdk2 kinases are the most active
kinase complex at the G1 to S-phase transition, their
kinase activity is thought to be most important in triggering this transition. Furthermore, cyclin E is an E2F
target gene and the best available evidence has suggested that among pocket proteins, pRB is primarily
responsible for regulating its expression [43,66]. This is
in part because cyclin E is deregulated in RB1 deficient
cells whereas loss of the other pocket proteins don’t
affect its expression [43,93], but also because only pRB
negatively regulates the activator E2Fs that are essential
to induce transcription of the cyclin E gene [92]. For
these reasons the feed forward loop that ensures that
cells advance to S-phase irreversibly relies on cyclin E/
cdk2 phosphorylation of pRB to release activator E2Fs
that transcribe more cyclin E and generate more kinase
activity towards pRB, leading to more free E2Fs and ultimately even more cyclin E (Figures 2 and 4). At the
same time p27KIP1 is also phosphorylated and targeted
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for degradation, allowing cyclin E/cdk2 to become maximally active [79]. Once cells have committed to S-phase
progression and initiated DNA synthesis, cyclin E/cdk2
will phosphorylate other cyclin E subunits and this will
target them for degradation, thus bringing the surge in
cyclin E/cdk2 activity to an end. The other pocket proteins are also phosphorylated in a manner that is analogous to pRB releasing their associated E2F transcription
factors [21]. Furthermore, a portion of these pocket proteins are exported from the nucleus where they go on to
form abundant complexes with repressor E2Fs in the
cytoplasm [94,95]. This is particularly true of p107
whose expression is greatly elevated by cell cycle entry
because it is an E2F target gene. Conversely, p130
expression continues to decline as the cell cycle
advances in part due to its proteolytic degradation [96],
consequently, cytoplasmic complexes between it and
E2Fs are relatively inabundant [21].
The point of no return for cell cycle entry has often
been termed the ‘restriction point’. Recent work measuring E2F transcription in single cells offers fresh insight
into the importance of the pRB-E2F regulatory interaction in G1-S control [97]. This report suggests that
release of E2F from pRB control by phosphorylation
coincides specifically with the point in which cells are
obligated to complete the rest of the cell cycle. Therefore to thoroughly understand this intricate step in the
cell cycle, it is important to review the specifics of how
exactly phosphorylation controls pRB-E2F interactions.
The RB protein contains 16 consensus cyclin dependent kinase phosphorylation sites that span the spacer
region as well as both N- and C-terminal regions, but
appear to be largely excluded from the small pocket
[98-100]. Early in the G1 phase of the cell cycle, D-type
cyclins along with cdk4 and cdk6 phosphorylate pRB,
prior to cdk2 activation [77,79]. Late in G1, cyclin E/
cdk2 further phosphorylates pRB, completely disrupting
its ability to bind E2F complexes. The sequential phosphorylation of pRB by ckd4/6 followed by cdk2 is necessary because cdk4/6 alone is unable to completely
phosphorylate pRB whereas cdk2 cannot use unphosphorylated pRB as a substrate [101]. Mutation of individual phosphorylation sites in pRB does not disrupt the
ability to block cell proliferation, indicating that no single site regulates pRB and E2F binding [99,100]. Instead
it has been shown that the majority of phosphorylation
sites on pRB need to be modified to abrogate E2F binding. Furthermore, it has been demonstrated that phosphorylation of multiple regions such as the spacer and
C-terminus together are necessary for displacement of
E2Fs from pRB [99]. Analysis of CDK phosphorylation
of p107 and p130 is much less extensive than for pRB.
However, databases of phosphoproteomic data such as
PhosphositePlus suggest that p107 and p130 are also
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phosphorylated in similar regions surrounding the
pocket domain [102].
Once free of regulation from pRB, activator E2Fs
associate with histone acetyl transferase enzymes such
as p300 [103] (Figure 2). These enzymes mediate acetylation of histone H3 and H4, allowing for transcription
of E2F target genes to ensure sufficient supplies of
nucleotides and other factors necessary for completing S
phase of the cell cycle [103].
Progression through S-phase

Our understanding of pocket proteins in cell cycle control is strongly influenced by the idea that pRB and its
family members are inactivated at the start of S-phase
and therefore functionless until dephosphorylated and
reactivated at the end of mitosis. While this paradigm is
supported by a number of lines of evidence, exceptions
to this rule are beginning to surface.
A number of reports indicate that pRB and E2F1 complexes are either resistant to cyclin/CDK phosphorylation, or that they exist in S-phase, thus implying
resistance to control by CDKs [104-106]. This apparent
paradox in E2F regulation can be explained by the fact
that pRB possesses two mechanisms to interact with
E2F transcription factors and one of them is unique to
E2F1 and is resistant to phosphorylation [107,108] (Figure 1B). While the function of this complex is not
entirely clear, pRB bound to E2F1 in its CDK resistant
configuration has altered DNA binding specificity compared with canonical pocket protein-E2F complexes
[107]. One possibility is that hyperphosphorylated pRB
bound to E2F1 represses transcription of select, proapoptotic E2F target genes such that E2F1’s apoptotic
function can be inhibited while its ability to drive proliferation is activated [108].
When cells experience DNA damage during S-phase
they need to arrest replication and repair the damage
before proceeding. This S-phase checkpoint function has
been shown to be absent in RB1 deficient cells, defining
a role for pRB in this process [109]. Following DNA
damage in S-phase, pRB is dephosphorylated and this
allows it to mediate the repression of cyclin A transcription. This causes a subsequent decrease in cdk2 activity
and decreased proliferating cell nuclear antigen tethering to chromatin, thereby disrupting DNA replication
[110,111]. Furthermore, it has also been shown that pRB
can physically localize to replication origins in S-phase
to arrest DNA synthesis, although the molecular
mechanism by which it blocks synthesis is unknown
[112]. While it is possible that phosphorylated pRB in
association with E2F1 may mediate some of these Sphase effects, protection of pRB from phosphorylation
has also been described. For pRB to localize on chromatin at replication origins during S-phase, it has been
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suggested that a small proportion of pRB is protected
from cyclin dependent kinases at these regions. This is
supported by the fact that inhibition of the phosphatase
PP2A causes pRB to be lost from these regions of the
genome [112]. Furthermore, it has been shown that pRB
is acetylated in response to DNA damage and this modification blocks recognition of pRB by cyclin dependent
kinases [113]. Thus, in addition to being inducibly
dephosphorylated during S-phase [114], pRB can also be
marked to remain active in the face of high levels of
cyclin dependent kinase activity [113,115]. Taken
together, this narrative on pocket protein function in Sphase reveals a role for these proteins in arresting cell
cycle advancement during this phase. In addition, some
details of the mechanism that activates pRB and allows
it to block DNA synthesis or inhibit apoptosis are
emerging.
The role of pocket proteins in navigating mitosis

In addition to their roles in the G1 and S phases, the
pocket proteins have also been implicated in controlling
events during mitosis. In previous sections it has been
discussed that E2F target genes are induced to function
in S-phase. However, some E2F target genes are induced
later and function in G2 or mitosis. Thus, misregulation
of E2F target genes early in the cell cycle because of
defects in pocket protein function can be manifested
later in mitotic errors. For example, pRB deficient cells
have a characteristic over expression of mitotic checkpoint genes Emi1 and Mad2, which are both E2F
responsive targets. This over expression delays the progression through mitosis and results in binucleated,
aneuploid, and polyploid cells [116,117]. Furthermore, in
nocodazole arrested cells, defective licensing of DNA
replication in RB1 deficient cells leaves them more
prone to re-replicate DNA following failure to progress
through mitosis [118,119]. These cells ultimately resume
proliferating with increased ploidy.
Beyond these E2F dependent effects on mitosis, nonE2F dependent roles in controlling chromosome architecture are also performed by RB family proteins. Deficiency for all three pocket proteins results in mitotic
errors caused by faulty chromatin structure in pericentromeric regions [120]. These mitotic errors most frequently cause cells to become tetraploid. It has also
been suggested that this role in chromosome packaging
during mitosis is mostly carried out by pRB since a
knock in mouse strain that is defective for LXCXE interactions also has this defect even though p107 and p130
proteins are functional. On a molecular level defective
pRB function in mitosis prevents condensin II loading
onto mitotic chromosomes [121-123]. This results in
defective chromosome congression at the metaphase
plate and merotelic attachments between microtubules
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and centromeres. Ultimately these defects manifest in
lagging anaphase chromosomes [122,123]. Similar mitotic phenotypes have been observed in cells deficient for
all pocket proteins suggesting that this function is primarily carried out by pRB [124].
Lastly, at the end of mitosis pocket proteins are
dephosphorylated to regulate E2Fs and guide progression in the ensuing G1 phase. Dephosphorylation has
been extensively studied for pRB and while it has been
thought to be primarily mediated by protein phosphatase 1 (PP1), reports of protein phosphatase 2 acting on
pRB have emerged more recently [125-127]. Intriguingly,
a direct contact site for PP1 on pRB has been identified
and it corresponds to the same short peptide sequence
used by cyclin/CDK complexes to bind and phosphorylate pRB [128] (Figure 1B). What this means is that the
principal phosphatases and kinases that modify pRB
must compete with one another for substrate access. In
functional terms this creates an additional level of regulation in which PP1’s ability to dephosphorylate is accelerated because it simultaneously inhibits CDK access to
pRB as a substrate [128]. This competition mechanism
is likely unique to pRB because the cyclin/CDK binding
sites in p107 and p130 lack an embedded RVXF motif
used by PP1 [128]. Importantly, PP1-pRB complexes are
most abundant in mitosis, suggesting that this mechanism is part of pRB activation at mitotic exit [129]. In
contrast, only protein phosphatase 2 has been shown to
dephosphorylate p107 and p130 [130,131].

The role of pocket proteins in cell cycle exit
The preceding sections of this review have highlighted
the roles played by RB family proteins in a typical mammalian cell cycle. In addition to ensuring fidelity in
replication and cell division, they are also critical to
orchestrating a cell’s exit from proliferation. This occurs
either as a checkpoint to repair DNA damage before
resuming proliferation, or it can be more permanent as
in terminal differentiation during development where
cells ultimately move into a G0 like state. The ensuing
sections are meant to provide a basic overview of how
cell cycle exit is controlled by pocket proteins. A number of examples of cell cycle exit are used to highlight
how the different pocket proteins participate in this process. Outlining the intricacies of all known RB-dependent cell cycle arrest events is beyond the scope of this
review. The following examples were selected because
they offer some of the best insight into the unique roles
of the different RB-family proteins during this process.
Activation of pocket proteins during a reversible cell
cycle arrest

As explained in the earlier section on progression
through G1, this is the cell cycle phase where pocket
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proteins are best able to influence cell cycle decisions.
For this reason RB-family dependent cell cycle arrest in
G1 requires the inhibition of cyclin dependent kinases
to keep pocket proteins underphosphorylated and active.
The members of the INK4 and CIP/KIP families of
cyclin dependent kinase inhibitors play a crucial role in
this activation step (Figure 4). One mechanism of pocket
protein activation is in response to DNA damage. Following DNA double strand breaks, p53 is activated and
induces expression of p21CIP1 [14]. This inhibitor then
blocks activity of cyclin dependent kinases and prevents
the phosphorylation of RB-family proteins. This will
ensure that cells remain in the G1 phase of the cell
cycle because the pocket proteins will remain hypophosphorylated. If DNA damage occurs in S-phase, as
described in a previous section of this article, phosphatases are also necessary to dephosphorylate RB-family
proteins to ensure they are capable of binding E2F transcription factors [114]. DNA damage offers one of the
best examples of how an exogenous stimulus can communicate growth arrest signals to central regulators of
proliferation like the pocket proteins.
Another informative example of an extra cellular signal leading to inactivation of cyclin dependent kinases
and activation of RB family proteins is during an arrest
that is stimulated by the growth suppressing cytokine
TGF-b. In particular, this example demonstrates differences among pocket proteins and how they contribute
to a cell cycle arrest. Like DNA damage, TGF-b signaling directly induces expression of cyclin dependent
kinase inhibitor proteins [132]. In epithelial cells the
INK4 protein p15 INK4B is induced by TGF-b [133].
Since INK4 proteins can only bind and inhibit activity
of cyclin D associated kinases, part of the inhibitory
mechanism involves the displacement of CIP/KIP proteins such as p27KIP1 from D-type cyclins so that they
are free to inhibit cyclin E or cyclin A associated kinases
[132]. TGF-b signaling also inhibits degradation of
p27 KIP1 , further ensuring that this inhibitor molecule
increases in abundance [134]. TGF-b blocks cell cycle
advancement in the G1 phase [135], for this reason its
actions serve to arrest cells that have already progressed
to G1 and then maintain pocket proteins in an active,
hypophosphorylated state. In this circumstance, pRB is
required to repress expression of E2F target genes [76].
Furthermore, a complex containing Smad2/3, p107, and
E2F4/5 is recruited to the c-Myc promoter to repress its
transcription in response to TGF-b [136]. Intriguingly,
this co-Smad role for p107 and E2F4/5 can be activated
by TGF-b signaling at any stage of the cell cycle. This
suggests that individual pocket proteins have highly specialized roles in responding to cell cycle arrest signals.
Furthermore, recent evidence also suggests non-E2F
dependent roles for pRB in TGF-b cell cycle arrest,
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further emphasizing the diverse nature of pocket protein
function in this cell cycle arrest paradigm [137].
TGF-b signaling induces proliferative arrest in many
cell types. The cyclin dependent kinase inhibitors that it
regulates vary between these cells. Each of p15 INK4B ,
p21CIP1 , and p57KIP2 are transcriptionally upregulated
individually, or in combination, depending on the cell
type in question [132]. This points to the importance of
cyclin dependent kinase inhibition in maintaining pocket
proteins in an active state in G1 (Figure 4). Further evidence of the importance of the whole RB-family in cell
cycle arrest is exemplified by the ectopic expression of
the p16INK4A protein in cells deficient for different combinations of pocket proteins. Loss of pRB, or the combined loss of p130 and p107, both abrogate p16 INK4A
induced cell cycle arrest, revealing a broad requirement
for pocket proteins in responding to cyclin dependent
kinase inhibition [138]. These experiments suggest that
collectively the pocket protein family participates in cell
cycle arrest that is stimulated by exogenous signals such
as TGF-b.
Recruitment of chromatin regulating factors by pocket
proteins in senescence

The TGF-b arrest mechanism described above is reversible, implying that once the growth arrest signal is
removed cell proliferation can resume. However, prolonged stimulation by TGF-b, or chronic genotoxic stimuli such as DNA breaks or telomere attrition, can
cause cells to enter a permanent arrest known as senescence [139]. This subsection of the review will discuss
the functions of RB-family proteins in establishing a permanent cell cycle arrest. RB-family dependence in senescence is well supported by experiments using mouse
embryonic fibroblasts deficient for all pocket proteins,
because these cells fail to senesce in response to oncogenic Ras or ectopic expression of cyclin dependent
kinase inhibitors [140-142]. Similarly, disruption of just
pRB and p107 abrogates Ras-induced senescence and
results in uncontrolled proliferation. Furthermore, loss
of pRB in already senescent cells leads to a reversal of
this cell cycle arrest and a resumption of proliferation
[142,143]. Thus, these studies collectively emphasize
roles for the whole RB-family, as the phenotypes of individual gene knock outs can’t account for deregulated
proliferation found in triple deficient cells.
As above, cell cycle arrest in senescence is initiated
through increased expression of cyclin dependent kinase
inhibitors; in particular p16INK4A expression is induced
in senescence. Once activated, the pocket proteins can
repress transcription of E2F targets and cause the cell
cycle to arrest. Since this also happens in reversible cell
cycle arrest, there has been considerable interest in
mechanisms that establish long term gene silencing at
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E2F targets [144]. As described earlier, the pocket proteins contain a well-conserved binding cleft that mediates interactions with LXCXE containing proteins
involved in transcriptional repression [53]. Importantly,
RB-family proteins can interact with E2Fs and LXCXE
proteins simultaneously. This allows pocket proteins to
recruit LXCXE containing proteins, particularly ones
that have chromatin regulating activity, to the promoters
of E2F-responsive genes where they are responsible for
condensation of chromatin and inhibition of transcription. Chromatin remodeling enzymes that have been
identified to bind to RB-family proteins include SWI/
SNF remodeling factors such as BRG and BRM, histone
deacetylases (HDAC1, 2 and 3), and histone methyltransferases (Suv39h1 and 2), among others [145-152].
The diversity of these interacting proteins allows the
pocket proteins to exert widespread effects on chromatin structure. For example, pRB has been associated
with decreased histone acetylation and increased H3K9
and H3K27 trimethylation at the promoters of E2F target genes [153]. By mediating histone deacetylation, as
well as methylation, pRB contributes to the formation of
heterochromatin [153]. Taken together, this suggests
that pRB may facilitate a reversible arrest by deacetylating histones and directing a more permanent arrest
through histone methyltransferases and gene silencing.
Indeed, key cell cycle E2F target genes are reported to
be silenced by pRB and a side by side comparison
revealed that p107 and p130 are dispensable for regulation of these same genes [154]. Furthermore, cells from
a gene targeted mutant mouse strain in which pRB is
unable to interact with LXCXE motif containing proteins demonstrates that pRB can support the initial
entry into senescence, but can’t permanently silence
transcription. Histones at E2F target genes fail to be
methylated, and transcription of these targets is activated by ectopic E2F expression [155]. Assembly of heterochromatin is often undertaken in promyelocytic
leukemia (PML) bodies, and pRB and E2Fs are associated with PML in senescence [156]. This places pRB
in the heart of the mechanism that assembles heterochromatin during senescence.
The ability to recruit chromatin remodeling enzymes
to the promoters of E2F target genes is not limited to
pRB alone, as both p107 and p130 can repress E2F
activity through recruitment of histone deacetylases
[157,158]. However, there is less evidence for p107 or
p130 recruiting histone methyltransferases, consistent
with pRB having a unique role in gene silencing. Work
by Shamma et al. offers an example of p130 recruiting
Suv39h1 to E2F gene promoters in senescence to
methylate histones in the absence of pRB [159]. Other
reports have demonstrated that the mammalian
DREAM complex containing p130 plays a key role in
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the maintenance of senescence [160,161]. In this scenario Dyrk kinases phosphorylate the Lin52 subunit in
the DREAM complex and this facilitates assembly with
p130 and gene silencing of E2F targets in the maintenance of senescence.
Beyond the regulation of transcription at specific E2F
target genes, senescent human cells are often characterized by senescence associated heterochromatic foci
(SAHF) [162]. These are heterochromatin bodies containing individual chromosomes that have been shown
to be associated with pRB mediated repression of E2F
target genes and their formation is dependent on pRB
function [163,164]. These heterochromatin structures
have many features in common with inactive X-chromosomes suggesting that pRB function in senescence is key
to triggering large scale chromatin changes as a downstream consequence [165].

Conclusions
The sections described above are in no way meant to
recap all of the important contributions in pocket protein research but rather to provide an overview of the
advances that have shaped our understanding of pocket
protein function in cell cycle regulation. There are many
fundamental questions in proliferative control that
remain to be answered. From this work, some basic
principles of pocket protein function may be emerging.
For example, the sections on G1 to S-phase transition
and cell cycle exit both illustrate the role for pRB in
transition from one phase to another, or from proliferation to arrest. In this sense pRB is less critical in a
population of rapidly proliferating or quiescent cells, but
becomes more important when cells are faced with decisions to enter or exit a proliferative state. In general, the
roles of p107 and p130 proteins are less central to cell
cycle decisions. Instead, the abundance of p130 and the
regulation of its assembly into the DREAM complex
suggests that its role is most crucial in the maintenance
of prolonged cell cycle arrest such as in quiescence or
senescence. This may offer some insight into why the
RB1 gene is mutated in cancer, but the RBL2 gene
(encoding p130) is generally spared. While pRB’s and
p130’s roles and periods of activity are becoming clearer
in relation to one another, p107 remains an enigma.
Comparisons between cells deleted for the genes encoding all pocket proteins and those deleted for pRB and
p130 together demonstrate a clear contribution of p107
to the overall role of RB-family proteins in cell cycle
control. However, there are few circumstances in which
p107 has a biochemical function that isn’t replaceable
by other pocket proteins. Responsiveness to TGF-b and
suppression of c-Myc transcription appears to be its sole
unique function [136], and even this has yet to be
demonstrated to be essential for TGF-b growth
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suppression. Future work on RB-family proteins will
need to continue to uncover unique roles for these proteins, only then will we truly understand how they collectively regulate cell proliferation.
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